Dr. Stefan Walzer
MAP - Market Access Podcast
Market Access (or alternatively reimbursement) in health care is THE key competence in order to be commercially successful with a new drug, medical device or digital health application. However, given the fact that market access is a complex field involving various disciplines and is an ever-changing field, it is difficult to be up to speed with the different evolvements across the world. MAP is THE bi-weekly Market Access Podcast provided by MArS Market Access & Pricing Strategy, which is your health care consultancy in the German-speaking markets and allows you to keep up to date with market...
Be sure to visit the podcast's website and support the creator: marketaccess-pricingstrategy.de
Author
Dr. Stefan Walzer
Category
Podcast website
Latest episode
Nov 15, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
How Will the EU JCA Reshape National HTA Across Europe, Dr. Oriol Solà-Morales? 15.11.2026 39:36
Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA? In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales , physician, health economist, founder and CEO of HITT and founding member of EUnetHTA, about what the first JCA reports reveal. Drawing on Spain's shift from regional to coordinated HTA, Oriol sees the JCA's potential...
How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng? 01.11.2026 38:54
AI is reshaping health economics and outcomes research (HEOR) – but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the loop” versus “AI in the loop” and why the two complement rather than contradict each other. Haidong explains why HEOR teams should reshape entire workflows – from evidence retrieva...
Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture? 15.10.2026 45:24
When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health policy attorney with eight years at the Centers for Medicare & Medicaid Services, to unpack the US “most favored nation” approach to drug pricing and the three CMMI models behin...
What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann? 01.10.2026 41:41
In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation — and what has to change for new therapies to reach patients. Bringing an investor's lens, Rainer explains why so many promising European companie...
How Do You Build a High-Performing Team in Pharma, Dr. Maurice Kléber? 15.09.2026 39:17
In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes — drawing on 18 years of leadership and a shared love of ice hockey. They discuss why trust and psychological safety are the foundation of any high-performing team, how role clarity and shared accountability turn a group of individuals into a...
Where Does AI Really Add Value in Market Access, Dr. Seye Abogunrin? 01.09.2026 38:18
Everyone wants AI to click the button for them — the real question is whether you still need to click it at all. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Seye Abogunrin, a health economist at Roche, Switzerland, to move AI in market access from experimentation to execution. They explore where AI adds real value today — drafting dossier text, screenin...
Why Should Early Health Economics Move Upstream, Dr. Björn Schwander & Julie Frappier? 15.08.2026 29:24
By the time most health economists get pulled in, the recipe is already set. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with two industry veterans — Dr. Björn Schwander, Founder of AHEAD GmbH and a specialist in early health economic modeling, and Julie Frappier, senior health economist and Founder of TOWWERS — to make the case for moving early health economics...
How Are Data Privacy Laws Delaying Patient Access to New Treatments, Douglas Drake and Adam Skali? (Repost) 01.08.2026 34:58
This is a repost of a popular episode of MAP - Market Access Podcast, from March 1st 2025. In this episode of MAP, Dr. Stefan Walzer, together with experts Douglas Drake and Adam Skali, unpacks the complexities of how GDPR regulations affect real-world evidence, cross-border studies, and market access in Europe. The discussion highlights data privacy challenges, delays in commercialization, and th...
How Did MFN Turn Swiss Pricing into an Industrial Policy Problem, Dr. Marcel Boller? 15.07.2026 33:02
When Bern sets a price, Washington now listens. In this episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Marcel Boller, Pharma and Medtech Expert and Partner at Werder Viganò in Zurich, to unpack why Swiss pricing reform has shifted from a reimbursement question into an industrial policy one. With Switzerland now in the US "Most Favored Nation" (MFN) reference baske...
Is the EU "Launch Obligation" Really as Scary as It Sounds, Dr. Alexander Natz? 01.07.2026 32:08
In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Alexander Natz, Secretary-General of EUCOPE, to unpack the biggest regulatory shifts reshaping pharmaceutical market access across Europe right now. They discuss how the EU Joint Clinical Assessment (JCA) now starts national HTA timelines as soon as a marketing authorization is filed, why the so-called "...
Dynamic Rebates, Drug Tenders & AMNOG: Is Germany Rewriting the Rules for Pharma, Thomas Hammerschmidt? 15.06.2026 37:40
Tune in to the newest episode of MAP, the Market Access Podcast, where Dr. Stefan Walzer engages in an insightful discussion with Prof. Dr. Thomas Hammerschmidt, a leading expert in Pharmaceutical Management at the Technical University of Applied Sciences (TH Rosenheim) in Bavaria. Together, they explore the latest proposals influencing AMNOG, pharmaceutical pricing, reimbursement, and market acce...
Wie finanziert Deutschland Gesundheitsinnovation, ohne den Patientenzugang zu gefährden, Afschin Gandjour? 08.06.2026 36:20
In der deutschsprachigen Spezialfolge des MAP – Market Access Podcast spricht Dr. Stefan Walzer mit Prof. Dr. Afschin Gandjour , Arzt, Gesundheitsökonom und Finanzexperte, über eine der zentralen gesundheitspolitischen Fragen dieser Wochen: Was bedeuten Finanzkommission und Referentenentwurf konkret für den Arzneimittelmarkt? Reicht ein dynamischer Herstellerabschlag – oder braucht es Kosten‑Nutze...
What lessons can Market Access teams learn from an Olympic medalist, Livia Altmann? 01.06.2026 39:14
From Olympic ice to AI-powered leadership: What can Market Access teams learn from elite sports? In the 111+1 anniversary episode of MAP – the Market Access Podcast , Dr. Stefan Walzer interviews Livia Altmann , a former Swiss Olympic ice hockey player who has transitioned into a leadership and "Human Intelligence 2.0" expert. Together, they explore how mental training, consistency, and energy man...
How Are UK NICE and US IRA/MFN Rewriting Global Pharma Pricing, Sreeram Ramagopalan? 15.05.2026 30:36
In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer speaks with Sreeram Ramagopalan, a global expert at the intersection of biotech value, HTA, real‑world evidence and market access. Together they unpack how the UK NICE threshold increase (from £20–30k to £25–35k per QALY) and US reforms (IRA, MFN) are quietly rewriting the rules for global launch sequencing and pricing str...
How Can Europe Move from Innovation Paradox to Powerhouse, Cuno Moser? 01.05.2026 38:40
In the latest episode of MAP – the Market Access Podcast, Dr. Stefan Walzer engages with Swiss healthcare strategist Cuno Moser to explore Europe's "innovation paradox" in healthcare. Despite its strengths in research, data quality, and clinical expertise, Europe struggles to transform pilot projects into scalable, reimbursable solutions. With over 27 fragmented reimbursement systems in the EU and...
Are primary research platforms adapting to payer dynamics, Shrutya Bhalla? 15.04.2026 38:57
In the latest episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with pricing and access expert Shrutya Bhalla about how primary research must evolve in an era of AI, policy shocks, and accelerating market complexity. The key takeaway: high‑quality primary research is no longer just about collecting insights – it must enable real strategic choices on pricing, access, launch seque...
How Can Political Leadership Turn Health into an Economic Priority, Hatice Küçük Benton? 01.04.2026 40:32
In this episode of the MAP – Market Access Podcast, Dr. Stefan Walzer speaks with Hatice Küçük Beton, Executive Director of the G20 Health and Development Partnership, about how to make global health truly investable – and keep it on the political agenda once the immediate crisis fades. They explore why high-level leadership, from Angela Merkel’s role during Germany’s G20 presidency to Japan’s joi...
Is Europe Still More Attractive Than the US, China, India or MENA for Medtech Investment, Bernard Bichsel? 15.03.2026 34:42
In the latest Market Access Podcast episode, host Stefan Walzer sits down with Bernard “Bernie” Bichsel – one of Europe’s most experienced voices in medtech regulation and former Head of the Medical Devices Division at Swissmedic – to unpack how regulation and market access truly fit together. They discuss why medical device regulation in Europe is still young compared to pharma, why the MDR/IVDR...
From Necessary Tasks to New Insights: How Can AI Act as a Sparring Partner in Market Access, Helmut Butscher? 01.03.2026 39:40
In this episode, Stefan Walzer talks with experienced Market Access manager Helmut Butscher about concrete AI applications across the full Market Access value chain. They explore how AI accelerates systematic literature reviews, unlocks real‑world evidence from complex data sources, supports HTA dossier preparation, and enables smarter decisions on pricing, reimbursement and global launch sequenci...
Can Innovative Contracting Turn High‑Cost Therapies into Sustainable Deals, Omar Ali? 15.02.2026 52:58
In this thought‑provoking Market Access Podcast episode, host Stefan Walzer sits down with Omar Ali – Head of Payers at Vipora, former NICE advisor, and one of the sharpest minds in drug pricing and innovative contracting to unpack where drug pricing and reimbursement are really heading. They explore why cost‑effectiveness thresholds are making market access tougher than ever, how uncertainty arou...
What Makes Australia’s HTA Approach to Equity and Health Productivity Unique, Zanfina Ademi? 01.02.2026 42:42
In this Market Access Podcast episode, Dr. Stefan Walzer sits down with Prof. Zanfania Ademi, a health economist at Monash University, to explore how Australia’s healthcare system is tackling key issues in market access and health technology assessment. Discover how Australia blends international approaches and new methods being developed by Zanfina and her team like distributional cost-effectiven...
No Decisions for Us, Without Us: Why Patient Advocacy Matters in Market Access, Erica Bersin? 15.01.2026 34:48
In this episode of the Market Access Podcast, Erica Bersin—founder of ERO Health Communications—joins Dr. Stefan Walzer to discuss the changing role of patient involvement in healthcare. Drawing on her experience in both Europe and the U.S., Erica explains how single-payer systems make patient engagement easier, while the U.S. faces more challenges but also unique advocacy opportunities. She highl...
Can VR and AR Finally Break Through the Barriers in Medical Innovation, Günther Illert? 15.12.2025 35:02
In this episode of the Market Access Podcast, Dr. Stefan Walzer sits down with strategy consultant and XR advocate Günther Illert to explore how virtual, augmented, and extended reality are reshaping healthcare—from patient training and pain therapy to surgical planning and medtech education. Learn how cross-sector collaboration and early adoption—especially outside traditional reimbursement syste...
Why Should Pharma and MedTech Innovators Look at New Zealand, Julius Ohrnberger? 01.12.2025 38:02
Tune in to this new episode of MAP to explore New Zealand’s unique healthcare and reimbursement landscape with Dr. Stefan Walzer and health economist Dr. Julius Ohnberger. Learn how PHARMAC combines HTA and payer roles, why equity and Māori health outcomes are central to market access and what global pharma can gain from launching in Aotearoa. Key insights include why New Zealand’s HTA model...
Are We Ready for a Cultural Shift Toward AI in Pharma, Elizabeth Shanahan? 15.11.2025 37:13
In this brand new episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Elizabeth Shanahan, AI Strategy Lead at Sanofi, for a refreshingly honest conversation on the real-world implementation of artificial intelligence in pricing, evidence generation, and HTA processes. From streamlining evidence generation to enhancing pricing strategies and dossier creation, they explore h...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.